UNSPSC 51124202: Disopyramide

This classification denotes a cation channel blocker and antiarrhythmic agent with the molecular formula C21H29N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) GFO928U8MQ, chemically known as 2-pyridineacetamide, alpha-(2-(diisopropylamino)ethyl)-alpha-phenyl- but more generally known as disopyramide, which bears US NIH Compound Identifier 3114. European Medicines Agency schedules Disopyramide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07237MIG.

UNSPSC 51124202 Disopyramide, a Commodity code, covers pharmaceutical procurement by state and local health agencies, including emergency medical services, health and human services departments, and multistate cooperative purchasing alliances. State and local governments buy specific branded or generic medications through this code — both individual emergency medications like epinephrine and labetalol for first-responder use, and broader generic multi-source pharmaceutical and over-the-counter product contracts serving state facilities. The solicitations reveal purchasing through direct manufacturer contracting, authorized wholesale distribution networks, and cooperative vehicles; vendors must demonstrate FDA compliance, Good Manufacturing Practices certification, Drug Supply Chain Security Act (DSCSA) compliance, and ability to meet expiration-dating and shelf-life requirements, often with performance penalties for reporting or delivery failures.

Recent activity spans Florida municipal fire rescue programs, multistate cooperative purchasing administered by state departments of administration, and state health and human services commissions exploring direct-to-manufacturer models. The City of Tampa issued an IFB in April 2026 for Advanced Life Support Medications (Bid No. 26-P-00188) with a response deadline of April 8, 2026 and an estimated contract value of $40,000, requiring four specific medication line items with nine-month minimum expiration dating and ten-day delivery, sheltered for Small Local Business Enterprises with a 5 percent bid discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP in January 2026 with a March 26, 2026 response deadline for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with contracts effective July 1, 2026. The Texas Health and Human Services Commission posted an RFI in early April 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs, signaling future formal procurement in that state.